박셀바이오 / 2025.03.11 사업보고서
1. 요약재무정보
가. 요약연결재무정보
(단위 : 원)
구 분
(단위 : 원)
제15기
제14기
제13기
(2024.12.31)
(2023.12.31)
(2022.12.31)
[유동자산]
39,104,918,000,000
51,227,395,000,000
20,898,449,000,000
ㆍ현금및현금성자산
7,820,812,000,000
9,046,236,000,000
389,661,000,000
[비유동자산]
37,841,684,000,000
33,752,801,000,000
3,264,596,000,000
자산총계
76,944,022,000,000
84,980,196,000,000
24,163,045,000,000
[유동부채]
2,820,285,000,000
924,141,000,000
307,042,000,000
[비유동부채]
2,129,615,000,000
562,787,000,000
528,736,000,000
부채총계
4,949,900,000,000
1,486,928,000,000
835,778,000,000
[자본금]
11,496,600,000,000
11,496,600,000,000
7,611,500,000,000
[결손금]
(54,413,487,000,000)
(43,537,101,000,000)
(33,383,030,000,000)
자본총계
71,994,122,000,000
83,493,268,000,000
23,327,267,000,000
구 분
(단위 : 원)
(2024.01.01. ~2024.12.31)
(2023.01.01. ~2023.12.31)
(2022.01.01 ~2022.12.31)
매출액
1,898,934,000,000
13,723,000,000
-
영업이익(손실)
(15,037,699,000,000)
(11,507,177,000,000)
(8,212,602,000,000)
법인세비용차감전순이익(손실)
(10,623,546,000,000)
(10,274,079,000,000)
(6,825,051,000,000)
총포괄손익
(10,876,386,000,000)
(10,154,071,000,000)
(6,878,076,000,000)
기본주당손익(손실)(단위: 원)
(463)
(524)
(358)